Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Walsh, S L; Preston, K L; Bigelow, G E; Stitzer, M L

doi:10.1016/s0022-3565(25)10510-7

Cited by 283Opioid Use Disorder TreatmentPain Management and Opioid UseNeuropeptides and Animal Physiology

Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Walsh, S L, Preston, K L, Bigelow, G E, Stitzer, M L·1995·The Journal of Pharmacology and Experimental Therapeutics

DOI 10.1016/s0022-3565(25)10510-7

Open this paper in CoChat — free account

Abstract

Buprenorphine, a mixed opioid agonist-antagonist, is being investigated as a treatment for opioid dependence. This study compared the acute subjective and physiological effects of sublingual buprenorphine to those of p.o. methadone over a wide range of doses and compared the ability of both drugs to alter the effects of an opioid challenge. Male inpatient volunteers (n = 9) with histories of opioid abuse participated in this double-blind, double-dummy study. Sublingual buprenorphine (0, 0.5, 2, 8, 16 and 32 mg) and p.o. methadone (3.75, 15 and 60 mg) were administered once weekly according to a Latin-square design, and subjects were monitored on a variety of physiological and subjective measures. Twenty-four hours later, subjects were tested with ascending doses of i.m. hydromorphone (0, 1 and 4 mg) given 45 min apart. Buprenorphine and methadone produced typical opioid agonist effects of long duration, including pupillary constriction, respiratory depression and elevations on subject-rated and observer-rated indices of euphoria, sedation and opioid-like symptoms. The buprenorphine dose-effect curves were nonlinear and maximal effects for most physiological and subjective measures were observed between 4 and 8 mg, with no greater effects observed at higher doses. The methadone dose-effect curves were linear across the range of doses tested. High doses of buprenorphine and methadone both attenuated the response to hydromorphone challenge 24 hr later. These data indicate that there is a ceiling on the effects of buprenorphine in humans that may reduce its abuse liability and increase its safety, and indicate that opioid blockade occurs after acute administration of buprenorphine or methadone.

Integrity signals

Registry

Crossref · 10.1016/s0022-3565(25)10510-7

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Buprenorphine's ceiling on agonist activity limits its abuse liability and reduces the probability of respiratory depression and overdose death, giving it a safety profile superior to methadone.
“Buprenorphine’s ceiling on its agonist activity limits its abuse liability and reduces the probability of respiratory depression and overdose death, resulting in a safety profile superior to methadone.27”
From A Preliminary Study Comparing Methadone and Buprenorphine in Patients with Chronic Pain and Coexistent Opioid Addiction (2013) · cites this paper as [27]

Still being checked.

Sorted by citations

Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986 · see citing works
Opioids and the treatment of chronic pain: Controversies, current status, and future directions.
Rosenblum, A., Marsch, L. A., Joseph, H., & Portenoy, R. K. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013628 · Cited by 648 · see citing works
A Comparison of Levomethadyl Acetate, Buprenorphine, and Methadone for Opioid Dependence
Johnson, R. E., Chutuape, M. A., Strain, E. C., Walsh, S. L., Stitzer, M. L., & Bigelow, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431802 · Cited by 623 · see citing works
Self-citation
Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
Uchtenhagen, A. (2009) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-17408 · Cited by 487 · see citing works
1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466 · see citing works
DRUG AND ALCOHOL DEPENDENCE
Vastrad, D., Chaudhary, G., & Ronad, S. V. (1962) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1976.tb140860.x · Cited by 393 · see citing works
Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats
Dahan, A., Yassen, A., Bijl, H., Romberg, R. R., Sarton, E. Y., Teppema, L. J., Olofsen, E., & Danhof, M. (2005) · British Journal of Anaesthesia · doi:10.1093/bja/aei145 · Cited by 323 · see citing works
Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers
Greenwald, M. K., Johanson, C.-E., Moody, D. E., Woods, J. H., Kilbourn, M. R., Koeppe, R. A., Schuster, C. R., & Zubieta, J.-K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300251 · Cited by 320 · see citing works
Buprenorphine vs Methadone Maintenance Treatment for Concurrent Opioid Dependence and Cocaine Abuse
Schottenfeld, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830200041006 · Cited by 300 · see citing works
Buprenorphine: Considerations for Pain Management
Johnson, R. E., Fudala, P. J., & Payne, R. (2005) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2004.07.005 · Cited by 290 · see citing works
Buprenorphine: how to use it right
Johnson, R. E. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00060-7 · Cited by 239 · see citing works
Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine
Kress, H. G. (2008) · European Journal of Pain · doi:10.1016/j.ejpain.2008.04.011 · Cited by 237 · see citing works
Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial
Magura, S., Lee, J. D., Hershberger, J., Joseph, H., Marsch, L., Shropshire, C., & Rosenblum, A. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.08.006 · Cited by 223 · see citing works
Opioid dependence treatment: options in pharmacotherapy
Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903037168 · Cited by 219 · see citing works
The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic
WALSH, S. L. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00056-5 · Cited by 218 · see citing works
Self-citation
Principles of laboratory assessment of drug abuse liability and implications for clinical development
Carter, L. P., & Griffiths, R. R. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.003 · Cited by 208 · see citing works
Comparison of Pharmacological Treatments for Opioid-Dependent Adolescents
Marsch, L. A., Bickel, W. K., Badger, G. J., Stothart, M. E., Quesnel, K. J., Stanger, C., & Brooklyn, J. R. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.10.1157 · Cited by 203 · see citing works
Comparing the subjective, psychomotor, and physiological effects of intravenous hydromorphone and morphine in healthy volunteers
Hill, J. L., & Zacny, J. P. (2000) · Psychopharmacology · doi:10.1007/s002130000500 · Cited by 194 · see citing works
Principles of initial experimental drug abuse liability assessment in humans
Griffiths, R. R., Bigelow, G. E., & Ator, N. A. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00098-x · Cited by 190 · see citing works
Self-citation
Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: A multicenter, randomized, double-blind, placebo-controlled trial
Sittl, R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90019-1 · Cited by 184 · see citing works
Prescription Opioids in Pregnancy and Birth Outcomes: A Review of the Literature
Desai, R. J., Brogly, S. B., & Yazdy, M. M. (2015) · Journal of Pediatric Genetics · doi:10.1055/s-0035-1556740 · Cited by 182 · see citing works
Twelve Reasons for Considering Buprenorphine as a Frontline Analgesic in the Management of Pain
Davis, M. P. (2012) · The Journal of Supportive Oncology · doi:10.1016/j.suponc.2012.05.002 · Cited by 181 · see citing works
A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain
Gudin, J. A., & Fudin, J. (2020) · Pain and Therapy · doi:10.1007/s40122-019-00143-6 · Cited by 180 · see citing works
Discontinuation of Buprenorphine Maintenance Therapy: Perspectives and Outcomes
Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.12.011 · Cited by 176 · see citing works
Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy
Greenwald, M. K., Comer, S. D., & Fiellin, D. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.07.035 · Cited by 174 · see citing works
Evaluation of Opioid Modulation in Major Depressive Disorder
Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169 · see citing works
Prenatal Buprenorphine Versus Methadone Exposure and Neonatal Outcomes: Systematic Review and Meta-Analysis
Brogly, S. B., Saia, K., Walley, A. Y., Du, H. M., & Paola Sebastiani, B. (2014) · American Journal of Epidemiology · doi:10.1093/aje/kwu190 · Cited by 168 · see citing works
From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States
Jaffe, J. H. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00055-3 · Cited by 162 · see citing works
Increasing opiate abstinence through voucher-based reinforcement therapy.
Silverman, K., Wong, C. J., Higgins, S., Brooner, R., Montoya, I., Contoreggi, C., Umbricht-Schneiter, A., Schuster, C., & Preston, K. (1996) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(96)01246-x · Cited by 158 · see citing works
Self-citation
The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers
WALSH, S. L., Nuzzo, P. A., Lofwall, M. R., & Holtman, J. R. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.05.007 · Cited by 146 · see citing works
Self-citation
Six deaths linked to concomitant use of buprenorphine and benzodiazepines
Reynaud, M., Petit, G., Potard, D., & Courty, P. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.93913859.x · Cited by 146 · see citing works
Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.
Amass, L., Ling, W., Freese, T. E., Reiber, C., Annon, J., Cohen, A. J., McCarty, D., Reid, M., Brown, L., Clark, C., et al. (2004) · American Journal on Addictions · doi:10.1080/10550490490440807 · Cited by 151 · see citing works
The role of human drug self-administration procedures in the development of medications
Comer, S. D., Ashworth, J., Foltin, R. W., Johanson, C. E., Zacny, J. P., & WALSH, S. L. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.001 · Cited by 145 · see citing works
Self-citation
Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence
Schottenfeld, R. S., Chawarski, M. C., Pakes, J., Pantalon, M. V., Carroll, K. M., & Kosten, T. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.340 · Cited by 145 · see citing works
Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats
Stinus, L., Cador, M., Zorrilla, E. P., & Koob, G. F. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300487 · Cited by 139 · see citing works
Sex Differences in Kappa Opioid Receptor Function and Their Potential Impact on Addiction
Chartoff, E. H., & Mavrikaki, M. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00466 · Cited by 134 · see citing works
Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine
Harris, D. S., Jones, R. T., Welm, S., Upton, R. A., Lin, E. T., & Mendelson, J. E. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00126-5 · Cited by 131 · see citing works
Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet.
Amass, L., Kamien, J. B., & Mikulich, S. K. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00074-5 · Cited by 136 · see citing works
A Liquid Chromatographic-Electrospray Ionization-Tandem Mass Spectrometric Method for Determination of Buprenorphine, Its Metabolite, norBuprenorphine, and a Coformulant, Naloxone, That Is Suitable for in Vivo and in Vitro Metabolism Studies
Moody, D. E., Slawson, M. H., Strain, E. C., Laycock, J. D., Spanbauer, A. C., & Foltz, R. L. (2002) · Analytical Biochemistry · doi:10.1006/abio.2002.5673 · Cited by 128 · see citing works
Transdermal Buprenorphine
Evans, H. C., & Easthope, S. E. (2003) · Drugs · doi:10.2165/00003495-200363190-00003 · Cited by 128 · see citing works
Home Buprenorphine/Naloxone Induction in Primary Care
Lee, J. D., Grossman, E., DiRocco, D., & Gourevitch, M. N. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0866-8 · Cited by 120 · see citing works
Diversion and abuse of buprenorphine: Findings from national surveys of treatment patients and physicians
Johanson, C., Arfken, C. L., di Menza, S., & Schuster, C. R. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.019 · Cited by 114 · see citing works
Buprenorphine tapering schedule and illicit opioid use
Ling, W., Hillhouse, M., Domier, C., Doraimani, G., Hunter, J., Thomas, C., Jenkins, J., Hasson, A., Annon, J., Saxon, A., et al. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02455.x · Cited by 112 · see citing works
A preclinical comparison between different opioids: antinociceptive versus adverse effects
Meert, T. F., & Vermeirsch, H. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.12.002 · Cited by 112 · see citing works
Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health‐related quality of life assessment
Giacomuzzi, S. M., Riemer, Y., Ertl, M., Kemmler, G., Rößler, H., Hinterhuber, H., & Kurz, M. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00352.x · Cited by 112 · see citing works
An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence
Rothman, R. B. (2000) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(99)00074-4 · Cited by 112 · see citing works
The pharmacological treatment of opioid addiction—a clinical perspective
Lobmaier, P. P. K., Gossop, M., Waal, H., & Bramness, J. G. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0793-6 · Cited by 111 · see citing works
Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco
Carter, J., Zevin, B., & Lum, P. J. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0149-1 · Cited by 110 · see citing works
Naltrexone and buprenorphine combination in the treatment of opioid dependence
Gerra, G., Fantoma, A., & Zaimovic, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060835 · Cited by 106 · see citing works
Management of chronic pain in the elderly: focus on transdermal buprenorphine
Vadivelu, N., & Hines, R. L. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s1880 · Cited by 103 · see citing works
Buprenorphine in the United States: Motives for abuse, misuse, and diversion
Chilcoat, H. D., Amick, H. R., Sherwood, M. R., & Dunn, K. E. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.07.005 · Cited by 100 · see citing works
Characterisation and monitoring of postoperative respiratory depression: current approaches and future considerations
Ayad, S. S., Khanna, A. K., Iqbal, S. U., & Singla, N. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.05.044 · Cited by 100 · see citing works
Treatment of heroin dependence with buprenorphine in primary care
Fiellin, D. A., Pantalon, M. V., Pakes, J. P., O'Connor, P. G., Chawarski, M., & Schottenfeld, R. S. (2002) · The American Journal of Drug and Alcohol Abuse · doi:10.1081/ada-120002972 · Cited by 98 · see citing works
Roles of μ-Opioid Receptors and Nociceptin/Orphanin FQ Peptide Receptors in Buprenorphine-Induced Physiological Responses in Primates
Cremeans, C. M., Gruley, E., Kyle, D. J., & Ko, M. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194308 · Cited by 97 · see citing works
Use of thermal threshold response to evaluate the antinociceptive effects of butorphanol in cats
Lascelles, B. D. X., & Robertson, S. A. (2004) · American Journal of Veterinary Research · doi:10.2460/ajvr.2004.65.1085 · Cited by 93 · see citing works
Concurrent buprenorphine and benzodiazepines use and self‐reported opioid toxicity in opioid substitution treatment
Nielsen, S., Dietze, P., Lee, N., Dunlop, A. J., & Taylor, D. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01731.x · Cited by 93 · see citing works
Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers
Comer, S. D., Walker, E. A., & Collins, E. D. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0023-6 · Cited by 91 · see citing works
Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia
WINSTOCK, A. R., Lea, T., & Sheridan, J. L. (2008) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2007.03.002 · Cited by 91 · see citing works
A Preliminary Study Comparing Methadone and Buprenorphine in Patients with Chronic Pain and Coexistent Opioid Addiction
Neumann, A. M., Blondell, R. D., Jaanimägi, U., Giambrone, A. K., Homish, G. G., Lozano, J. R., Kowalik, U., & Azadfard, M. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.759872 · Cited by 90 · see citing works
Differences in the profile of neonatal abstinence syndrome signs in methadone‐ versus buprenorphine‐exposed neonates
Gaalema, D. E., Scott, T. L., Heil, S. H., Coyle, M. G., Kaltenbach, K. A., Badger, G. J., Arria, A. M., Stine, S. M., Martin, P., & Jones, H. E. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.04039.x · Cited by 90 · see citing works
Pharmacokinetics and Subjective Effects of Sublingual Buprenorphine, Alone or in Combination with Naloxone
Harris, D. S., Mendelson, J. E., Lin, E. T., Upton, R. A., & Jones, R. T. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443050-00005 · Cited by 87 · see citing works
Prognostic Factors in Buprenorphine- versus Methadone-Maintained Patients
Schottenfeld, R. S., Pakes, J., & Kosten, T. R. (1998) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199801000-00006 · Cited by 87 · see citing works
Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing
Johnson, R. E., Eissenberg, T., Stitzer, M. L., Strain, E. C., Liebson, I. A., & Bigelow, G. E. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(95)01189-7 · Cited by 86 · see citing works
Self-citation
Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet
Schuh, K. J., & Johanson, C. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00012-5 · Cited by 82 · see citing works
Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing
Marsch, L. A., Bickel, W. K., Badger, G. J., & Jacobs, E. A. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.08.011 · Cited by 81 · see citing works
Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder
WALSH, S. L., Comer, S. D., Lofwall, M. R., Vince, B. D., Levy‐Cooperman, N., Kelsh, D., Coe, M. A., Jones, J. D., Nuzzo, P. A., Tiberg, F., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1874 · Cited by 81 · see citing works
Self-citation
Sleep disordered breathing in patients receiving therapy with buprenorphine/naloxone
Farney, R. J., McDonald, A., Boyle, K. M., Snow, G. L., Nuttall, R. T., Coudreaut, M. F., Wander, T. J., & Walker, J. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00120012 · Cited by 79 · see citing works
Buprenorphine: An Analgesic with an Expanding Role in the Treatment of Opioid Addiction
Robinson, S. E. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00235.x · Cited by 78 · see citing works
Differential tolerance to antinociceptive effects of µ opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats
Walker, E. A., & Young, A. M. (2001) · Psychopharmacology · doi:10.1007/s002130000620 · Cited by 78 · see citing works
The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers
Middleton, L. S., Nuzzo, P. A., Lofwall, M. R., Moody, D. E., & Walsh, S. L. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03424.x · Cited by 77 · see citing works
Self-citation
Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans
Comer, S. D., Collins, E. D., & Fischman, M. W. (2001) · Psychopharmacology · doi:10.1007/s002130000623 · Cited by 77 · see citing works
Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity
Toce, M. S., Chai, P. R., Burns, M. M., & Boyer, E. W. (2018) · Journal of Medical Toxicology · doi:10.1007/s13181-018-0685-1 · Cited by 90 · see citing works
Relative bioavailability of different buprenorphine formulations under chronic dosing conditions
Strain, E. C., Moody, D. E., Stoller, K. B., WALSH, S. L., & Bigelow, G. E. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.11.008 · Cited by 75 · see citing works
Self-citation
Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder
Nasser, A. F., Greenwald, M. K., Vince, B. D., Fudala, P. J., Twumasi‐Ankrah, P., Liu, Y., Jones, J. P., & Heidbreder, C. A. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000434 · Cited by 72 · see citing works
Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction
Tzschentke, T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1003-8 · Cited by 71 · see citing works
Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans.
Amass, L., Kamien, J. B., & Mikulich, S. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00141-1 · Cited by 79 · see citing works
Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies
Stoops, W. W., Hatton, K. W., Lofwall, M. R., Nuzzo, P. A., & WALSH, S. L. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1942-4 · Cited by 69 · see citing works
Self-citation
NOVEL METABOLITES OF BUPRENORPHINE DETECTED IN HUMAN LIVER MICROSOMES AND HUMAN URINE
Chang, Y., Moody, D. E., & McCance‐Katz, E. F. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006148 · Cited by 69 · see citing works
Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine–glucuronide in plasma by liquid chromatography–tandem mass spectrometry
Polettini, A. E., & Huestis, M. A. (2001) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(01)00029-9 · Cited by 69 · see citing works
Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans
Schuh, K. J., WALSH, S. L., & Stitzer, M. L. (1999) · Psychopharmacology · doi:10.1007/s002130051045 · Cited by 68 · see citing works
Self-citation
Sublingual Buprenorphine and Methadone Maintenance Treatment: A Three-Year Follow-Up of Quality of Life Assessment
Giacomuzzi, S. M., Ertl, M., Kemmler, G., Riemer, Y., & Vigl, A. (2005) · The Scientific World JOURNAL · doi:10.1100/tsw.2005.52 · Cited by 68 · see citing works
Buprenorphine: The Basic Pharmacology Revisited
Cowan, A. (2007) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31806c9202 · Cited by 67 · see citing works
Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth
Warden, D., Subramaniam, G., Carmody, T. J., WOODY, G. E., Minhajuddin, A., Poole, S. A., Potter, J. S., Fishman, M. J., Bogenschutz, M. P., Patkar, A. A., et al. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.04.011 · Cited by 66 · see citing works
Demystifying Buprenorphine Misuse: Has Fear of Diversion Gotten in the Way of Addressing the Opioid Crisis?
Doernberg, M., Krawczyk, N., Agus, D., & Fingerhood, M. (2019) · Substance Abuse · doi:10.1080/08897077.2019.1572052 · Cited by 66 · see citing works
The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review
Dunn, K. E., Sigmon, S. C., Strain, E. C., Heil, S. H., & Higgins, S. T. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.05.033 · Cited by 65 · see citing works
“Third, buprenorphine has a ceiling on its agonist effects that reduces the risk for buprenorphine-related overdose, making it a good candidate for use in outpatient settings (Banks, 1979; Jasinski et al., 1978; Lewis, 1985; Mello and Mendelson, 1980; Walsh et al., 1994; Walsh et al., 1995).”
Background
Buprenorphine Pharmacodynamics and Pharmacokinetics
WALSH, S. L., & Middleton, L. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6974-2_12 · Cited by 63 · see citing works
Self-citation
Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain
Rauck, R. L., Potts, J., Xiang, Q., Tzanis, E. L., & Finn, A. L. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1128307 · Cited by 63 · see citing works
The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus
Pergolizzi, J. V., Mercadante, S., Echaburu, A. V., den Eynden, B. V., Fragoso, R. M., Mordarski, S., Lybaert, W., Beniak, J., Orońska, A., & Sláma, O. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902920731 · Cited by 63 · see citing works
Buprenorphine in the Treatment of Opiate Dependence
Wesson, D. R., & Smith, D. E. (2010) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2010.10400689 · Cited by 62 · see citing works
Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico
Garcia, C. A., Correa, G. C., Viver, A. D. H., Kinlock, T., Gordon, M., Avila, C. A., Reyes, I., & Schwartz, R. (2007) · Journal of addiction medicine · doi:10.1097/adm.0b013e31814b8880 · Cited by 53 · see citing works
Effects of intravenous patient-controlled analgesia with buprenorphine and morphine alone and in combination during the first 12 postoperative hours: A randomized, double-blind, four-arm trial in adults undergoing abdominal surgery
Oifa, S., Sydoruk, T., White, I. D., Ekstein, M. P., Marouani, N., Chazan, S., Skornick, Y. G., & Weinbroum, A. A. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.03.018 · Cited by 61 · see citing works
Thrice-weekly versus daily buprenorphine maintenance
Schottenfeld, R. S., Pakes, J., O’Connor, P. G., Chawarski, M. C., Oliveto, A. H., & Kosten, T. R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00270-x · Cited by 60 · see citing works
Comparable Analgesic Efficacy of Transdermal Buprenorphine in Patients Over and Under 65 Years of Age
Likar, R., Vadlau, E.-M., Breschan, C., Kager, I., Korak-Leiter, M., & Ziervogel, G. (2008) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181673b65 · Cited by 59 · see citing works
Buprenorphine and Naloxone for Heroin Dependence
Johnson, R. E., & McCagh, J. C. (2000) · Current Psychiatry Reports · doi:10.1007/s11920-000-0012-8 · Cited by 59 · see citing works
Flunitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat
Borron, S. W., Moníer, C., Risède, P., & Baud, F. J. (2002) · Human & Experimental Toxicology · doi:10.1191/0960327102ht303oa · Cited by 59 · see citing works
Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study
Gimbel, J. S., Spierings, E. L. H., Katz, N. P., Xiang, Q., Tzanis, E. L., & Finn, A. L. (2016) · Pain · doi:10.1097/j.pain.0000000000000670 · Cited by 57 · see citing works
Effectiveness and tolerability of the buprenorphinetransdermal system in patients with moderate to severe chronic pain: A multicenter, open-label, uncontrolled, prospective, observational clinical study
Muriel, C., Failde, I., Micó, J. A., Álvarez, M. N., & Sánchez‐Magro, I. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.04.007 · Cited by 55 · see citing works
Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review
Ahn, J. S., Lin, J., Ogawa, S., Chen, Y., O’Brien, T., Le, B. H. C., Bothwell, A., Moon, H., Hadjiat, Y., & Ganapathi, A. (2017) · Journal of Pain Research · doi:10.2147/jpr.s140320 · Cited by 55 · see citing works
Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification
Sobel, B.-F. X., Sigmon, S. C., WALSH, S. L., Johnson, R. E., Liebson, I. A., Nuwayser, E. S., Kerrigan, J. H., & Bigelow, G. E. (2003) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.08.006 · Cited by 55 · see citing works
Self-citation
Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain
Pergolizzi, J. V., & Raffa, R. B. (2019) · Journal of Pain Research · doi:10.2147/jpr.s231948 · Cited by 54 · see citing works

Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
Strain, E. C., Preston, K. L., Liebson, I. A., & Bigelow, G. E. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11174-9 · Cited by 88 · see citing works
Self-citation
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773 · see citing works
Self-citation
Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
Strain, E. C., Preston, K. L., Liebson, I. A., & Bigelow, G. E. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24449-4 · Cited by 70 · see citing works
Self-citation
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
Bickel, W. K., Stitzer, M. L., Bigelow, G. E., Liebson, I. A., Jasinski, D. R., & Johnson, R. E. (1988) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20047-7 · Cited by 226 · see citing works
Self-citation
Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine
Strain, E. C., WALSH, S. L., & Bigelow, G. E. (2001) · Psychopharmacology · doi:10.1007/s002130100920 · Cited by 53 · see citing works
Self-citation

Authors: Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L.
Affiliations: Johns Hopkins University (US)
ORCID: Walsh, S L
Preston, K L
Stitzer, M L
Venue: The Journal of Pharmacology and Experimental Therapeutics
Publisher: Elsevier BV
Published: 1995-07
Volume: 274
Issue: 1
Pages: 361-372
ISSN: 0022-3565 (ISSN-L)
DOI: 10.1016/s0022-3565(25)10510-7
OpenAlex: W2097145370
Cited by: 283
References: 0
Citations by year: 2025: 6 · 2024: 4 · 2023: 5 · 2022: 3 · 2021: 5 · 2020: 12 · 2019: 12 · 2018: 9 · 2017: 12 · 2016: 10 · 2015: 10 · 2014: 8 · 2013: 9 · 2012: 11
FWCI: 9.36
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
PubMed (publishedVersion)
PubMed
Funders: National Institutes of Health (5r18da006165-05, 5r18da006120-05)
National Institute on Drug Abuse (R18 DA 06165, K05DA000050, R18 DA06120)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords: buprenorphine, methadone, opioid agonist-antagonist, opioid blockade, opioid use disorder, opioid abuse, sublingual administration, dose-response relationship, ceiling effect, respiratory depression, miosis, euphoria, sedation, abuse liability
MeSH terms: Adult, Buprenorphine, Hydromorphone, Double-Blind Method, Humans, Male, Methadone, Narcotic Antagonists, Receptors, Opioid, Respiration, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Acute administration of buprenorphine in humans: partial agonist and blockade effects.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks